Democrats are committed to passing legislation this year to curb prescription drug prices, but they're still disagreeing on how to cut costs for patients and taxpayers while preserving profits that lure investors to back potentially promising treatments. It boils down to finding a balance: How big a stick should Medicare have to negotiate prices with pharmaceutical companies? With hundreds of billions of dollars in potential savings, the stakes are enormous.